Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22524385 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL6570375 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL12348668 | 0.88 | IDO1 (0.45) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL1944510 | 0.84 | IDO1 (0.58) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL30275532 | 0.84 | IDO1 (0.58) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL11852553 | 0.83 | PLAU (0.54) | PLAUIDO1MTNR1AMTNR1BHTR1A | |
| SCHEMBL8230626 | 0.79 | IDO1 (0.72) | PLAUIDO1MTNR1AMTNR1BHTR1A | |
| SCHEMBL10447404 | 0.79 | CYP1A2 (0.55) | CYP1A2CYP11B1CYP11B2PLAUIDO1 | |
| SCHEMBL4529303 | 0.77 | CYP11B2 (0.54) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL18264462 | 0.77 | FAAH (0.54) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251128-B1 | FORMULATIONS WITH A LOW PARTICLE CONTENT | MERCK PATENT GMBH (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-2517274-B1 | COMPOSITIONS COMPRISING POLYMERIC BINDERS | MERCK PATENT GMBH (DE) | 2017-05-24 | — | — | EP | disclosed |
| EP-3077475-A1 | COMPOSITIONS CONTAINING A POLYMERIC BINDER WHICH COMPRISES ACRYLIC AND/OR METHACRYLIC ACID ESTER UNITS | Merck Patent GmbH (DE) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015082037-A1 | COMPOSITIONS CONTAINING A POLYMERIC BINDER WHICH COMPRISES ACRYLIC AND/OR METHACRYLIC ACID ESTER UNITS | MERCK PATENT GMBH (DE) | 2015-06-11 | — | — | WO | disclosed |
| US-7674788-B2 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| US-7674788-B2 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | US | disclosed |
| US-6872743-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040063941-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-04-01 | — | — | US | disclosed |
| EP-1345898-A2 | TERACYCLIC CARBAZOLE DERIVATES AND THEIR USE AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| CN-1105100-C | Compounds with anti-inflammatory and immunosuppressive activity | ITALFARMACO SPA (IT) | 2003-04-09 | — | — | CN | disclosed |
| WO-2002050034-A2 | TETRACYCLIC CARBAZOLE DERIVATES AND THEIR USE AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| CN-1221403-A | Compounds with anti-inflammatory and immunosuppressive activity | ITALFARMACO SPA (IT) | 1999-06-30 | — | — | CN | disclosed |
| EP-0204975-B1 | PROCESS FOR PREPARING SUBSTITUTED TETRALONES | ETHYL CORPORATION (US) | 1991-07-17 | — | — | EP | disclosed |
| EP-0204975-A2 | Process for preparing substituted tetralones | ETHYL CORPORATION (US) | 1986-12-17 | — | — | EP | disclosed |
| US-4603221-A | 6-ALKOXYTETRALIN, TRANSITION METAL SALT, TERTIARY AMINE, AMMONIUM OR ALKALI METAL PERSULFATE, OXIDATION | ETHYL CORPORATION (US) | 1986-07-29 | — | — | US | disclosed |
| US-4294992-A | Process for the production of alkyl aryl ethers | THE SOUTHLAND CORPORATION (US) | 1981-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063941-A1 | Novel spla2 inhibitors | PLA2G12A, PLAAT2, SPINT2 | CYP1A2 2256/4885CYP3A4 3977/4885CYP2C9 4297/4885 |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE4C | CYP1A2 208/4885CYP3A4 75/4885CYP2C9 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.